Jacobs Levy Equity Management’s Protara Therapeutics TARA Stock Holding History

Jacobs Levy Equity Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	295,565 +245,310	+488%	+$1.17M	﹤0.01%	689
2026 Q1	$262K	Buy	+50,255	New	+$297K	﹤0.01%	892
2017 Q2	–	Sell	-1,807	Closed	-$126K	–	1013
2017 Q1	$126K	Buy	+1,807	New	+$135K	﹤0.01%	842

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Jacobs Levy Equity Management's TARA Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Protara Therapeutics (TARA) stake by 488% in Q2 2026, buying an estimated $1.17M and bringing the position to 295,565 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #689.

Jacobs Levy Equity Management first reported a position in TARA in Q1 2017 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

Jacobs Levy Equity Management held 295,565 shares of Protara Therapeutics worth $1.13M as of Q2 2026.
Jacobs Levy Equity Management bought 245,310 Protara Therapeutics shares in Q2 2026, an estimated $1.17M.
Protara Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #689 holding.
Jacobs Levy Equity Management first reported a position in Protara Therapeutics in Q1 2017 and has held it in 3 quarters since.
120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.